Alterity Therapeutics (ATHE) CEO David Stamler Buys 47,620 Shares

What Happened

• David Allen Stamler, CEO of Alterity Therapeutics (ATHE), reported a purchase of 47,620 shares at $0.50 per share, totaling $23,810, on 2026-08-31. The transaction is reported as a purchase (code P) and flagged as a "Derivative" transaction in the filing, indicating the shares were obtained through a derivative-related mechanism rather than a straightforward open-market trade.

Key Details

• Transaction date: 2026-08-31; reported filing date: 2026-09-08 (filed 8 days after the trade — appears late; Form 4s are normally due within 2 business days).
• Price: $0.50 per share; Shares acquired: 47,620; Total value: $23,810.
• Transaction code: P (purchase); filing labels the trade as "Derivative" — suggests conversion/exercise or other derivative-to-share transfer rather than a standard open-market buy. The original Form 4 should be consulted for exact mechanics.
• Shares owned after the transaction: Not disclosed in the summary data provided.
• No footnotes (e.g., 10b5-1 plan, tax withholding) were included in the provided details.

Context

• The dollar value of this purchase is relatively small for a CEO-level insider. Purchases can be interpreted as a positive signal, but this single, modest derivative-related acquisition alone does not establish a trend or clear insight into insider sentiment. Check the full Form 4 for precise mechanics and any additional disclosures.